Literature DB >> 9420052

Antiviral drug susceptibility of human herpesvirus 8.

J Neyts1, E De Clercq.   

Abstract

We studied the susceptibility of human herpesvirus 8 (HHV-8) to a number of antiherpesvirus agents. The acyclic nucleoside phosphonate (ANP) analogs cidofovir and HPMPA [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)adenine] effected potent inhibition of HHV-8 DNA synthesis, with 50% effective concentrations (EC50) of 6.3 and 0.6 microM, respectively. Adefovir, an ANP with both antiretrovirus and antiherpesvirus activity, blocked HHV-8 DNA replication at a fourfold-lower concentration than did foscarnet (EC50 of 39 and 177 microM, respectively). The most potent inhibitory effect was obtained with the N-7-substituted nucleoside analog S2242 (EC50, 0.11 microM). The nucleoside analogs acyclovir, penciclovir, H2G ((R)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine), and brivudine had weak to moderate effects (EC50 of > or =75, 43, 42, and 24 microM, respectively, and EC90 of > or =75 microM), whereas ganciclovir elicited pronounced anti-HHV-8 activity (EC50, 8.9 microM).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9420052      PMCID: PMC164202     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.

Authors:  R G Nador; E Cesarman; A Chadburn; D B Dawson; M Q Ansari; J Sald; D M Knowles
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

2.  Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma.

Authors:  W Zhong; H Wang; B Herndier; D Ganem
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma.

Authors:  S J Gao; L Kingsley; D R Hoover; T J Spira; C R Rinaldo; A Saah; J Phair; R Detels; P Parry; Y Chang; P S Moore
Journal:  N Engl J Med       Date:  1996-07-25       Impact factor: 91.245

4.  Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study.

Authors:  M J Glesby; D R Hoover; S Weng; N M Graham; J P Phair; R Detels; M Ho; A J Saah
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

5.  Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.

Authors:  D H Kedes; D Ganem
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

6.  Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs.

Authors:  R W Humphrey; T R O'Brien; F M Newcomb; H Nishihara; K M Wyvill; G A Ramos; M W Saville; J J Goedert; S E Straus; R Yarchoan
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

7.  Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.

Authors:  G Andrei; R Snoeck; D Reymen; C Liesnard; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

8.  Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.

Authors:  K C Cundy; P Barditch-Crovo; R E Walker; A C Collier; D Ebeling; J Toole; H S Jaffe
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  Kaposi's sarcoma-associated herpesvirus in non-AIDS related lymphomas occurring in body cavities.

Authors:  E Cesarman; R G Nador; K Aozasa; G Delsol; J W Said; D M Knowles
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

10.  The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients.

Authors:  L L Decker; P Shankar; G Khan; R B Freeman; B J Dezube; J Lieberman; D A Thorley-Lawson
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

View more
  34 in total

1.  Identification and rapid quantification of early- and late-lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesvirus agents.

Authors:  J P Zoeteweij; S T Eyes; J M Orenstein; T Kawamura; L Wu; B Chandran; B Forghani; A Blauvelt
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Recent Advances in the Management of Infections in Liver Transplant Recipients.

Authors:  Nina Singh
Journal:  Curr Infect Dis Rep       Date:  2001-04       Impact factor: 3.725

3.  Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir.

Authors:  E A Gustafson; R F Schinazi; J D Fingeroth
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men.

Authors:  Ashok Cattamanchi; Misty Saracino; Stacy Selke; Meei-Li Huang; Amalia Magaret; Connie Celum; Lawrence Corey; Anna Wald; Corey Casper
Journal:  J Med Virol       Date:  2011-10       Impact factor: 2.327

5.  Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cells.

Authors:  Natacha Coen; Sophie Duraffour; Lieve Naesens; Marcela Krecmerová; Joost Van den Oord; Robert Snoeck; Graciela Andrei
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

6.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

7.  Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses.

Authors:  Natacha Coen; Sophie Duraffour; Dimitri Topalis; Robert Snoeck; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

Review 8.  Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors:  Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal:  Chem Rev       Date:  2014-10-02       Impact factor: 60.622

9.  Human herpesvirus 8 gene encodes a functional thymidylate synthase.

Authors:  Gábor Gáspár; Erik De Clercq; Johan Neyts
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 10.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.